Matthew W. Foehr
Net Worth
Last updated:
What is Matthew W. Foehr net worth?
The estimated net worth of Mr. Matthew W. Foehr is at least $55,371,845 as of 13 May 2022. He owns shares worth $25,838,414 as insider, has earned $17,328,901 from insider trading and has received compensation worth at least $12,204,530 in Ligand Pharmaceuticals Incorporated.
What is the salary of Matthew W. Foehr?
Mr. Matthew W. Foehr salary is $938,810 per year as Pres & Chief Operating Officer in Ligand Pharmaceuticals Incorporated.
How old is Matthew W. Foehr?
Mr. Matthew W. Foehr is 52 years old, born in 1973.
What stocks does Matthew W. Foehr currently own?
As insider, Mr. Matthew W. Foehr owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated (LGND) | Pres & Chief Operating Officer | 173,354 | $149.05 | $25,838,414 |
What does Ligand Pharmaceuticals Incorporated do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Matthew W. Foehr insider trading
Ligand Pharmaceuticals Incorporated
Mr. Matthew W. Foehr has made 20 insider trades between 2012-2022, according to the Form 4 filled with the SEC. Most recently he purchased 2,500 units of LGND stock worth $206,910 on 13 May 2022.
The largest trade he's ever made was exercising 45,547 units of LGND stock on 4 Feb 2021. As of 13 May 2022 he still owns at least 173,354 units of LGND stock.
Ligand Pharmaceuticals Incorporated key executives
Ligand Pharmaceuticals Incorporated executives and other stock owners filed with the SEC:
- Mr. Charles S. Berkman (56) Senior Vice President, Gen. Counsel & Sec.
- Mr. John L. Higgins (55) Chief Executive Officer & Executive Director
- Mr. Matthew E. Korenberg (50) Executive Vice President of Fin. & Chief Financial Officer
- Mr. Matthew W. Foehr (52) Pres & Chief Operating Officer